VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
708.27
Molecular Formula
C34H42ClN9O4S
Notes
Research use only, not for human use.
Receptor
CDK
CAS Number
1209002-43-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items